Effect of early application of tirofiban on body status of patients with emergency ST segment elevation myocardial infarction after percutaneous coronary intervention

ZHA Shuangying; FENG Liuliu; LIU Tianhua; HUANG Hongman

doi:10.7619/jcmp.20201404

Journal of Clinical Medicine in Practice > 2021 > 25(3): 89-93. > DOI: 10.7619/jcmp.20201404

ZHA Shuangying, FENG Liuliu, LIU Tianhua, HUANG Hongman. Effect of early application of tirofiban on body status of patients with emergency ST segment elevation myocardial infarction after percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 89-93. DOI: 10.7619/jcmp.20201404

Citation:

PDF (680 KB)

Effect of early application of tirofiban on body status of patients with emergency ST segment elevation myocardial infarction after percutaneous coronary intervention

1.
Department of Special Examination for Heart, Shidong Hospital of Yangpu District in Shanghai, Shanghai, 200438
2.
Department of Cardiovascular Medicine, Shidong Hospital of Yangpu District in Shanghai, Shanghai, 200438

More Information

Received Date: November 09, 2020
Available Online: March 03, 2021
Published Date: March 03, 2021

Graphical Abstract

Abstract

Abstract

Objective To investigate the effect of early application of tirofiban on the inflammatory response, angiography and clinical outcome of patients with emergency ST segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI).
Methods Totally 123 STEMI patients with PCI were divided into observation group (n=65) and control group (n=58). The observation group was treated with tirofiban, and the control group was not treated with tirofiban. The levels of serum high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and procalcitonin (PCT) were compared between the two groups at hospital admission and 3 days after treatment. The recovery rate of TIMI grade 3 blood flow, corrected TIMI frame number, incidence rates of ST segment resolution higher than 75% at 90 min after operation, major adverse cardiac events (MACE) at 30 d and bleeding events during hospitalization were compared between the two groups. The influencing factors of MACE were analyzed by univariate and multivariate analysis.
Results After 3 days of treatment, hs-CRP, IL-6 and PCT in the observation group were significantly lower than those in the control group (P < 0.05). Compared with the control group, the recovery rate of TIMI grade 3 blood flow of infarction-related vessels in the observation group was significantly higher, the number of corrected TIMI frames was significantly lower, the incidence of ST segment resolution higher than 75% at 90 min after operation was significantly higher, and the incidence rate of MACE at 30 d was significantly lower (P < 0.05). Univariate analysis showed that the prevalence rate of diabetes, Killip cardiac function classification and serum creatinine in the MACE group were significantly higher than those in the non-MACE group, and the systolic blood pressure was significantly lower than that in the non-MACE group (P < 0.05). Multivariate analysis showed that cardiac function classification at admission, systolic blood pressure and early application of tirofiban were independent influencing factors of MACE (P < 0.05).
Conclusion Early application of tirofiban can reduce the inflammatory reaction, improve the angiographic and clinical results of emergency STEMI patients with PCI, and it is also an independent factor of MACE.
- tirofiban,
- ST segment elevation myocardial infarction,
- percutaneous coronary intervention,
- inflammatory response,
- angiography

FullText(HTML)

References (15)

References

[1]	TZIMAS G, ANTIOCHOS P, MONNEY P, et al. Atypical electrocardiographic presentations in need of primary percutaneous coronary intervention[J]. Am J Cardiol, 2019, 124(8): 1305-1314. doi: 10.1016/j.amjcard.2019.07.027
[2]	KUMAR J, O'CONNOR CT, KUMAR R, et al. Coronary no-reflow in the modern era: a review of advances in diagnostic techniques and contemporary management[J]. Expert Rev Cardiovasc Ther, 2019, 17(8): 605-623. doi: 10.1080/14779072.2019.1653187
[3]	YANG M, HUO X, MIAO Z, et al. Platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor Tirofiban in acute ischemic stroke[J]. Drugs, 2019, 79(5): 515-529.
[4]	KOZEL M, KOĈKA V, LISA L, et al. Immune-inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective[J]. Heart Vessels, 2019, 34(4): 557-563. doi: 10.1007/s00380-018-1281-7
[5]	中国医师协会急诊医师分会, 中华医学会心血管病学分会, 中华医学会检验医学分会. 急性冠脉综合征急诊快速诊疗指南[J]. 中华危重症医学杂志: 电子版, 2016, 9(2): 73-80.
[6]	中华医学会心血管病学分会介入心脏病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南(2016)[J]. 中华心血管病杂志, 2016, 44(5): 382-400. doi: 10.3760/cma.j.issn.0253-3758.2016.05.006
[7]	BETHEL M A, PATEL R A, MERRILL P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis[J]. Lancet Diabetes Endocrinol, 2018, 6(2): 105-113. doi: 10.1016/S2213-8587(17)30412-6
[8]	王成钢, 王春梅, 艾辉, 等. 高敏C-反应蛋白对急性ST段抬高型心肌梗死早期恶性心律失常的预测价值[J]. 心肺血管病杂志, 2019, 38(6): 589-592. doi: 10.3969/j.issn.1007-5062.2019.06.001
[9]	沈正, 刘兴德, 韦波, 等. 血清超敏C反应蛋白对冠状动脉粥样硬化性心脏病PCI手术患者危险分层与评估预后的价值[J]. 重庆医学, 2018, 47(1): 54-56. doi: 10.3969/j.issn.1671-8348.2018.01.019
[10]	祝聪聪, 胡良炎, 洪李锋, 等. 替罗非班对AMI患者介入治疗后炎症因子、内皮功能及心功能的影响[J]. 海南医学院学报, 2018, 24(10): 990-993.
[11]	ZHANG Z, LI W, WU W, et al. Myocardial reperfusion with Tirofiban injection via aspiration catheter: efficacy and safety in STEMI patients with large thrombus burden[J]. Herz, 2020, 45(3): 280-287. doi: 10.1007/s00059-018-4716-0
[12]	KARATHANOS A, LIN Y, DANNENBERG L, et al. Routine glycoprotein Ⅱb/Ⅲa inhibitor therapy in ST-segment elevation myocardial infarction: ameta-analysis[J]. Can J Cardiol, 2019, 35(11): 1576-1588. doi: 10.1016/j.cjca.2019.05.003
[13]	KAYMAZ C, KELȨN, ÖZDEMIR N, et al. The effects of Tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI[J]. Anatol J Cardiol, 2016, 15(11): 899-906. http://www.ncbi.nlm.nih.gov/pubmed/25868037
[14]	DANNENBERG L, WOLFF G, NAGUIB D, et al. Safety and efficacy of Tirofiban in STEMI-patients[J]. Int J Cardiol, 2019, 274: 35-39. doi: 10.1016/j.ijcard.2018.09.052
[15]	FABRIS E, OTTERVANGER J P, HERMANIDES R S, et al. Effect of early Tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention[J]. Catheter Cardiovasc Interv, 2019, 93(5): 293-297. doi: 10.1002/ccd.28043

Cited By

Cited by

Periodical cited type(9)

1.	王小雯，郭丽纳，王会敏，郭海星，石文博. 基于早期肺部CT定量检测评估中重度ARDS患者预后的价值. 中国CT和MRI杂志. 2025(03): 56-58 .
2.	曾渊杰，宋晓龙，薛寅. 大柴胡汤加减辅助治疗急性胰腺炎（腑实热结证）的临床观察. 中国中医急症. 2025(03): 491-494 .
3.	刘艳，帅玉婷，涂娇子，刘云，应志兰. 股动脉ECMO辅助治疗冠状动脉旁路移植术后患者预后不良的危险因素. 检验医学与临床. 2024(05): 707-711 .
4.	张方，王娜，孟君，赵智东，崔存晓，任成波. 肺泡灌洗液病原微生物宏基因二代测序技术在难治性肺炎治疗中的应用效果. 保健医学研究与实践. 2024(04): 78-83 .
5.	叶青，田瑞雪，侯洪颜，颜卫峰. 经鼻高流量氧疗对稳定期慢性阻塞性肺疾病合并高碳酸血症的疗效分析. 实用临床医药杂志. 2024(14): 67-71+76 . 本站查看
6.	施静，潘溢丹. 慢性阻塞性肺疾病急性加重患者高分辨率CT肺血管参数与肺功能、病情严重程度及预后相关性分析. 陕西医学杂志. 2024(12): 1649-1653 .
7.	胡建粤. 无创呼吸机联合氧驱动雾化吸入治疗慢性阻塞性肺病急性加重患者的疗效分析. 实用中西医结合临床. 2024(21): 46-49 .
8.	周晓兰，杨楠，温海娟，刘秀云，罗雪娇，武彦锋，刘岩峰，李岩. 基于临床特征、实验室指标分析多重耐药鲍曼不动杆菌感染重症肺炎患者预后不良的危险因素. 中国临床医生杂志. 2024(12): 1426-1429 .
9.	龚建，焦宪法. 重症监护室脓毒症休克患者进行山莨菪碱治疗的临床观察. 深圳中西医结合杂志. 2024(24): 120-123 .

Other cited types(1)

Get Citation

PDF

XML

Article views (203) PDF downloads (11) Cited by(10)

Turn off MathJax

Article Contents

Abstract

References

Effect of early application of tirofiban on body status of patients with emergency ST segment elevation myocardial infarction after percutaneous coronary intervention

Abstract

References

Cited by

Periodical cited type(9)

Other cited types(1)

Catalog

Export File

Citation

Format

Content